Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-OX40/TNFRSF4 Antibody-FITC (9R426) is a FITC-conjugated Rabbit antibody targeting OX40/TNFRSF4. Anti-OX40/TNFRSF4 Antibody-FITC (9R426) can be used in FCM.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 T | $35 | 7-10 days | 7-10 days | |
| 100 T | $104 | 7-10 days | 7-10 days |
| Description | Anti-OX40/TNFRSF4 Antibody-FITC (9R426) is a FITC-conjugated Rabbit antibody targeting OX40/TNFRSF4. Anti-OX40/TNFRSF4 Antibody-FITC (9R426) can be used in FCM. |
| Synonyms | TXGP1L, tumor necrosis factor receptor superfamily, member 4, OX40, IMD16, CD134, ACT35 |
| Ig Type | Rabbit IgG |
| Clone | 9R426 |
| Reactivity | Mouse |
| Specificity | Mouse OX40/TNFRSF4 |
| Verified Activity | Flow cytometric analysis of Mouse-OX40 expression on ConA-stimulated BABL/c splenocytesCells were stained with FITC-conjugated anti-Mouse-OX40. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
| Application | |
| Recommended Dose | 10 μl/Test, 0.1 mg/ml |
| Antibody Type | Monoclonal |
| Host Species | Rabbit |
| Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Mouse OX40 (rM OX40; TMPY-05020; NP_035789.1; Met1-Pro211) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| Research Background | OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
| Conjucates | FITC |
| Others Formats | Unconjugated/PE |
| Antibody Types Available | 3 |
| Immunogen | Recombinant Protein: Mouse OX40 Protein (TMPY-05020) |
| Antigen Species | Mouse |
| Biology Area | Cancer Drug Targets |
| Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
| Transport | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.